Response to Harper et al.  by Schumacher, Dagmar et al.
Cancer Cell
CorrespondenceResponse to Harper et al.Dagmar Schumacher,1 Boris Strilic,1 Kishor Kumar Sivaraj,1 Nina Wettschureck,1,2 and Stefan Offermanns1,2,*
1Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Ludwigstrasse 43, 61231 Bad Nauheim, Germany
2Medical Faculty, Johann Wolfgang Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
*Correspondence: stefan.offermanns@mpi-bn.mpg.de
http://dx.doi.org/10.1016/j.ccr.2013.08.015We thank Harper et al. for their comments
on our publication. The authors of this
correspondence point to some differ-
ences between our publication (Schu-
macher et al., 2013) and others with
regard to the in vitro phenotype of
Munc13-4-deficient platelets. Based on
our experimental data, we think that
Munc13-4 deficiency primarily blocks
the release from dense granules, but not
from a-granules of platelets. It is, how-
ever, well known that platelet activation
involves multiple positive feedback loops
and that the release of ATP/ADP from
dense granules can promote platelet
aggregation and a-granule release via
the autocrine and paracrine activation of
P2Y1 and P2Y12 receptors (Gachet,
2006; Kahner et al., 2006). Based on this
concept, it is indeed expected that loss
of ATP/ADP release from platelet dense
granules also affects, under certain
experimental conditions, the release of
a-granules from activated platelets, as
well as the aggregation of platelets.
Whether these secondary effects of a
blocked dense-granule release are seen
in vitro depends on the experimental con-
ditions used to study platelet function,
such as platelet concentration or the con-
centration and type of applied stimuli. At
intermediate thrombin concentrations,
we actually saw a tendency of reduced
PF4 release and integrin aIIbb3 activation
which, however, was not significant (Fig-
ures 2A and S2C in Schumacher et al.,
2013). In the experiments mentioned by
Harper et al., we used relatively low
platelet concentrations, reducing the
likelihood that sufficient amounts of ATP/
ADP are released to induce secondary288 Cancer Cell 24, September 9, 2013 ª201effects. Finally, at least in the case of
tumor-cell-induced platelet activation, it
is also possible that the small amount of
ATP released from tumor cells (see
Figure 1D in Schumacher et al., 2013)
obscured a somewhat reduced a-granule
release.
Whether the secondary effects of
dense-granule release are of relevance
for platelet-dependent tumor cell metas-
tasis is not known. Nevertheless, we
agree that solely on the basis of our
experiments performed with Munc13-4-
deficient platelets and animals, we would
not be able to exclude that defects other
than reduced dense granule secretion
also contribute to the observed defects
in transendothelial tumor cell migration
and in vivo metastasis. We therefore
mentioned in the discussion of this publi-
cation the possibility that ‘‘in addition to
ATP, other platelet-derived factors, such
as transforming growth factor b, promote,
in particular, later stages of tumor cell
extravasation (Labelle et al., 2011).’’
However, our study goes beyond the
description of the role of dense-granule
secretion in platelet-dependent tumor
cell transendothelial migration andmetas-
tasis. We also identified a downstream
mechanism by demonstrating that the
endothelial ATP receptor P2Y2 mediates
platelet-dependent tumor cell transmigra-
tion and that loss of P2Y2, which is not
present on platelets, strongly reduces
tumor cell metastasis from primary
tumors, as well as after intravenous injec-
tion of tumor cells. If the above described
secondary effects played a major role in
platelet dense-granule secretion-depen-
dent tumor cell transendothelial migration3 Elsevier Inc.and metastasis, we would expect the
phenotype of Munc13-4 deficiency to
be more severe than the phenotype of
P2Y2 deficiency. However, both platelet
Munc13-4 deficiency and endothelial
knockdown of P2Y2 abolished platelet-
dependent transendothelial tumor cell
migration. More importantly, tumor cell
metastasis in vivo, when studied in
bone-marrow chimeras, was reduced
both in P2Y2-deficient mice transplanted
with wild-type bone-marrow and in
P2Y2-deficient mice transplanted with
Munc13-4-deficient bone marrow to the
same degree, and no additive effect could
be seen.
Thus, while we acknowledge that loss
of dense-granule secretion in Munc13-
4-deficient platelets can lead under
certain experimental conditions to a sec-
ondary impairment of a-granule release,
we think that our data show that dense-
granule-derived ATP acting on P2Y2
receptors is the primary mechanism
through which blockade of ATP release
from Munc13-4-deficient platelets affects
tumor cell transendothelial migration and
metastasis.REFERENCES
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